CytRx Corporation (NASDAQ:CYTR) belongs to Healthcare sector. Its weekly performance is -0.96%. On last trading day company shares ended up $4.11. CytRx Corporation (NASDAQ:CYTR) distance from 50-day simple moving average (SMA50) is -0.14%. May 27, CytRx Corporation (NASDAQ:CYTR) announced an upcoming poster presentation regarding its lead drug candidate, aldoxorubicin, at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held May 29 – June 2, 2015 in Chicago.
Omeros Corporation (NASDAQ:OMER) shares moved down -0.75% in last trading session and ended the day at $19.85. OMER Gross Margin is 100.00% and its return on assets is -198.80%. Omeros Corporation (NASDAQ:OMER) quarterly performance is -4.89%. On May 22, Omeros Corporation (NASDAQ:OMER) announced that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Omidria® (phenylephrine and ketorolac injection) 1%/0.3%.
Novartis AG (NYSE:NVS) belongs to Healthcare sector. Its net profit margin is 24.50% and weekly performance is -1.97%. On last trading day company shares ended up $102.73. Novartis AG (NYSE:NVS) distance from 50-day simple moving average (SMA50) is 0.29%. Novartis (NYSE:NVS) announced data from the Phase III COMBI-d study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive metastatic melanoma when treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) compared to Tafinlar monotherapy alone. This is the first combination of BRAF/MEK inhibitors to demonstrate a statistically significant overall survival benefit for this patient population in two Phase III studies.
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) shares moved up 2.00% in last trading session and ended the day at $9.18. ARIA Gross Margin is 96.10% and its return on assets is -30.60%. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) quarterly performance is 12.92%. ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced long-term follow-up data from the Phase 1 trial of Iclusig® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). With a median follow-up of over four years (53.1 months), Iclusig continues to demonstrate anti-leukemic activity in chronic-phase (CP) CML patients with limited treatment options (n=43).
On 29 May, Curis, Inc. (NASDAQ:CRIS) shares moved up 3.69% and was closed at $3.37. CRIS EPS growth in last 5 year was -8.00%. Curis, Inc. (NASDAQ:CRIS) year to date (YTD) performance is 124.67%. Curis, Inc. (NASDAQ:CRIS), announced results from the completed dose escalation and ongoing expansion stages of a Phase 1 trial of CUDC-907, an oral dual inhibitor of histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) enzymes. Data were presented at the Annual Meeting of American Society of Clinical Oncology (ASCO) that is being held in Chicago, IL. At the recommended Phase 2 dose and schedule, CUDC-907 has demonstrated evidence of clinical activity with objective responses observed in patients with relapsed/ refractory diffuse large B cell lymphoma (DLBCL) and Hodgkin’s lymphoma (HL). Two complete responses (CRs) and 4 partial responses (PRs) were reported in 10 response evaluable patients with DLBCL, including 3 responses (1 CR and 2 PRs) in patients with transformed follicular lymphoma (t-FL/DLBCL), a very difficult to treat subset of DLBCL.